Deletion of haematopoietic Dectin-2 or CARD9 does not protect from atherosclerosis development under hyperglycaemic conditions.,Diabetes & Vascular Disease Research

当前位置： X-MOL 学术 › Diab. Vasc. Dis. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Deletion of haematopoietic Dectin-2 or CARD9 does not protect from atherosclerosis development under hyperglycaemic conditions.
Diabetes & Vascular Disease Research ( IF 2.4 ) Pub Date : 2019-12-23 , DOI: 10.1177/1479164119892140
Kathrin Thiem ₁ , Geerte Hoeke _{2,

3} , Enchen Zhou _{2,

3} , Anneke Hijmans ₁ , Tom Houben ₄ , Margien G Boels _{2,

5} , Isabel M Mol _{2,

3} , Esther Lutgens _{6,

7} , Ronit Shiri-Sverdlov ₄ , Johan Bussink ₈ , Thirumala D Kanneganti ₉ , Mariëtte R Boon _{2,

3} , Rinke Stienstra _{1,

10} , Cees J Tack ₁ , Patrick Cn Rensen _{2,

3} , Mihai G Netea _{1,

11} , Jimmy Fp Berbée _{2,

3} , Janna A van Diepen ₁

Affiliation

Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Departments of Molecular Genetics, Human Biology and Surgery, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands.
Division of Nephrology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Division of Experimental Vascular Biology, Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Institute for Cardiovascular Prevention, Ludwig Maximilians University of Munich, Munich, Germany.
Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands.
Department for Genomics and Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.

Diabetes largely increases the risk for the development of cardiovascular diseases (CVD), the leading cause of death in type 1 and type 2 diabetic patients. In fact, a 1% increase in haemoglobin (Hb) A_1c levels is associated with a 31% increase in cardiovascular events.¹ Interestingly, atherosclerotic plaques of diabetic patients display a higher macrophage content as compared to non-diabetic patients independently of other risk factors, which strongly correlates with HbA_1c levels.²

中文翻译：

在高血糖情况下，造血Dectin-2或CARD9的删除不能防止动脉粥样硬化的发展。

糖尿病会大大增加患心血管疾病（CVD）的风险，心血管疾病是1型和2型糖尿病患者的主要死亡原因。实际上，血红蛋白（Hb）A _1c水平增加1％与心血管事件增加31％有关。¹有趣的是，与非糖尿病患者相比，糖尿病患者的动脉粥样硬化斑块显示出更高的巨噬细胞含量，而与其他危险因素无关，这与HbA _1c水平密切相关。²

更新日期：2020-04-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>